>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Ciproxifan

Ciproxifan (Synonyms: FUB-359)

Catalog No.GC12924

시프록시판(FUB 359)은 9.2 nM의 IC50으로 히스타민 H3 수용체의 강력하고 선택적이며 경구 생체이용 가능한 경쟁적 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Ciproxifan Chemical Structure

Cas No.: 184025-18-1

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$82.00
재고 있음
5mg
US$75.00
재고 있음
10mg
US$111.00
재고 있음
50mg
US$445.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ciproxifan is a novel and potent antagonist of histamine H3-receptor with a IC50 value of 9.2±1.8nM [1].

Ciproxifan has shown the in-vitro antagonistic action to H3-receptor with a IC50 value of 9.2±1.8nM. In addition, Ciproxifan has been reported to competitively antagonize the (R) α-MeHA induced relaxation of electrically stimulated guinea pig ileum longitudinal muscle. Besides, Ciproxifan has been revealed to have the effect on [125I]iodoproxyfan binding with a Ki value of 0.7±0.2 nM. Apart from these, Ciproxifan has been found to be a selective antagonist with pKi values of 9.3, 4.9, 4.6, 5.5, 5.4, 4.9, <5.0, 4.8, <5.5 and <5.7 for H3, H2, H1, muscarinic M3, adrenergic α1D, β1, serotonin 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4, respectively [1].

References:
[1] Ligneau X1, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther. 1998 Nov; 287(2):658-66.

리뷰

Review for Ciproxifan

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ciproxifan

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.